Pfizer applies for initial approval in the United States of America
Pfizer and its partner Biontec have applied for emergency clearance in the United States to start distributing the vaccine.
The US Food and Drug Administration will determine whether the vaccine is safe or not.
No one has yet known how long is sufficient for the Food and Drug Administration to study the data and determine whether the vaccine is safe or not.
The experimental data of the vaccine confirmed that it protects against corona by 94% of those over the age of 65, and England had requested a course to obtain 40 million doses of the vaccine. It is expected that the approval of the license will come from the US Food and Drug Administration at the beginning of December, that is, during the first half of it.
The two companies stated that they would be willing to distribute the vaccine within hours of obtaining the license. And if the vaccine is approved, that will be much faster than the period usually required for approval of vaccines, as it will take place within 10 months of detailing the genetic code, while the average waiting for approval in the United States is about eight years.
Pfizer CEO Albert Burla said Thursday that the registration for emergency use was "a milestone in our journey to bring the Covid 19 vaccine to the world."
The first doses will be limited, and the Centers for Disease Control and Prevention will decide who should get them.
European Commission President Ursula von der Leyen said the EU could move quickly as well, by the end of the year.
But there are caveats. Stephen Evans, professor of pharmacological epidemiology at the London School of Hygiene and Tropical Medicine, said both the Food and Drug Administration and the European Medicines Agency would be conducting a "very careful assessment".